HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach

Featuring an interview with Dr John V Heymach, including the following topics:

• Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00)
• Activity of targeted agents across HER2 alterations in NSCLC (4:06)
• Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39)
• Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of therapy, including trastuzumab deruxtecan (T-DXd) and zongertinib (29:23)
• Case: A woman in her mid 50s with HER2-mutant NSCLC receives zongertinib with durable response (34:23)
• Case: A woman in her late 50s with HER2-mutant NSCLC receives multiple lines of therapy, including sevabertinib and T-DXd (39:53)
• Investigational approaches in HER2-mutant NSCLC (46:31)

CME information and select publications